

From: [REDACTED] [REDACTED]@novartis.com>

Sent: 22 February 2022 16:29

To: [REDACTED] <[REDACTED]@nhs.scot>

Cc: [REDACTED] <[REDACTED]@novartis.com>; [REDACTED]

<[REDACTED]@nhs.scot>

Subject: Gilenya (Fingolimod)

Hi [REDACTED]

I hope this email finds you well?

Please find an update to the Gilenya® (fingolimod) patent.

If you have any questions, please do let me know.

Further to our recent correspondence regarding our product Gilenya (fingolimod), you will be aware that Technical Board of Appeal (“**TBA**”) of the European Patent Office (“**EPO**”) decided to grant our patent application EP 2 959 894 (“**EP ‘894**”) with the title “*S1P Receptor Modulators for Treating Multiple Sclerosis*”. EP ‘894 protects the active ingredient fingolimod for use in the treatment of relapsing-remitting multiple sclerosis at a daily dosage of 0.5mg.

Whilst the marketing protection period for Gilenya expires on 22 March 2022, once formally granted (due approximately June/July 2022), the EP ‘894 patent will then expire on 25 June 2027 (unless revoked earlier in national proceedings or as a result of a successful opposition being filed before the EPO). Please note that Novartis initially filed its patent application covering the 0.5mg daily dose for Gilenya to treat relapsing remitting multiple sclerosis (“**RRMS**”) in 2007, and the application has been transparent and open to the public for years. However, Novartis required the intervening time to navigate the patent examination process, and ultimately to work with the EPO to obtain this patent covering our innovation. The duration of a patent is 20 years from the original filing date; therefore, the 2027 expiry date of this patent is in accordance with the standard timeline.

Novartis is aware that several generic pharmaceutical companies have applied for and obtained marketing authorisations in the UK for fingolimod. The licensed indication for Gilenya is the treatment of highly active RRMS and the approved dosage in adults is 0.5mg of fingolimod per day. Consequently, while EP ‘894 is in force, it would be an infringement of the patent for generic 0.5mg fingolimod products to launch in the UK, including by offering for sale, selling, importing, manufacturing or keeping fingolimod products.

Novartis remains at NHSS’s disposal, should any questions arise in connection with the above or should any additional documents be required.

Kind Regards

[REDACTED]

[REDACTED]

United Kingdom GM / REGION EUROPE PHARMA

Novartis Pharmaceuticals UK Limited
2nd Floor The West Works Building
White City Place
195 Wood Lane
London
W12 7FQ

T [REDACTED]
M [REDACTED]
[REDACTED]@novartis.com



Novartis Pharmaceuticals UK Ltd.
Registered in England 00119006
Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.